Lowcountry Infectious Diseases PA — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$58,426	34
2024	Research	$216,962	136
2023	Research	$126,341	34
2022	Research	$190,972	47
2021	Research	$154,224	10
2020	Research	$4,000	1

Breakdown

Who paid Research payments · program years 2020–2025

Insmed, Inc. $521,452 236 payments
Biohaven Pharmaceuticals, Inc. $154,224 10 payments
Biohaven Pharmaceutical Holding Company Ltd. $71,250 15 payments
Octapharma USA, Inc. $4,000 1 payment

Studies the money was for Research payments · program years 2020–2025

A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact $352,099 179 payments
Phase 2/3 Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of Zavegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients with COVID-19 Requiring Supplemental Oxygen $183,125 17 payments
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) $169,352 57 payments
Phase 2/3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of Zavegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients with COVID-19 Requiring Supplemental Oxygen $42,349 8 payments
Gam10-10 $4,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.